Which statins are best for lowering non-HDL cholesterol in high-risk patients?
A meta-analysis ranks the agents depending on the intensity of treatment required for cardio protection of patients with diabetes
Moderate-intensity treatment with rosuvastatin may be the best statin option for lowering non-HDL cholesterol in patients with diabetes who are at risk of cardiovascular disease, UK researchers say.
The group has conducted the first meta-analysis in such patients that is based on levels of non-HDL cholesterol (non-HDL-C) rather than LDL cholesterol (LDL-C), in line with UK guidelines recommending it as the primary target for reducing cardiovascular risk.
The University of Manchester-led study involved
